Subscribe: MedWorm: Hormonal Therapy
http://www.medworm.com/rss/medicalfeeds/therapies/Hormonal-Therapy.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
breast cancer  breast  cancer  hormonal therapy  hormone therapy  hormone  patients  prostate cancer  source  study  therapy  women 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Hormonal Therapy

MedWorm: Hormonal Therapy



MedWorm.com provides a medical RSS filtering service. Over 7000 RSS medical sources are combined and output via different filters. This feed contains the latest news and research in the Hormonal Therapy category.



Last Build Date: Tue, 29 Mar 2016 16:21:44 +0100

 



8 Things Every Woman Should Know About Her Libido

Mon, 28 Mar 2016 22:09:01 +0100

By Hallie Levine Here today, gone tomorrow--your libido can be puzzling, to say the least. But that ebb and flow is completely natural, says Lauren Streicher, MD, clinical associate professor of obstetrics and gynecology at Northwestern Memorial Hospital in Chicago: "All women go through periods when they feel especially frisky, as well as times when they just seem to have lost their mojo." Read on to learn about the many reasons your libido may come and go, and how to find it when you miss it. Curious about aphrodisiacs? We've got those too, from strawberries to Savasana. RELATED: 9 Things Every Woman Must Know About Her Fertility The brain is your biggest sex organ Your brain is where the spark starts. Five of the most important areas: Ventral striatum: A 2012 fMRI study found that this ...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.

Mon, 28 Mar 2016 21:23:02 +0100

Authors: Rydén L, Heibert Arnlind M, Vitols S, Höistad M, Ahlgren J Abstract Tamoxifen (TAM) and aromatase inhibitors (AI) are adjuvant therapy options for postmenopausal women with estrogen receptor positive (ER+) breast cancer. This systematic review of seven randomized controlled studies comparing TAM and AI, and one study comparing extended therapy with an AI with placebo after about 5 years of tamoxifen, aims to assess long-term clinical efficacy and adverse events. The literature review was performed according to the principles of the Cochrane Collaboration. The search included common databases up to 2013-01-14. Studies of high or moderate quality were used for grading of evidence. Revman™ software was utilized for meta-analyses of published data. Disease free survival (D...



Mp40-12 long-term oncological outcomes of salvage radical prostatectomy for radio-recurrent/persistent prostate cancer after radiation therapy.

Mon, 28 Mar 2016 19:24:11 +0100

Radiation therapy is a commonly used primary treatment for clinically localized prostate cancer (PCa). The majority of patients who fail primary radiation therapy will receive palliative hormonal therapy. However, a number of patients will have persistent/recurrent cancer in the prostate only and will benefit from salvage extirpative or ablative local therapy. (Source: The Journal of Urology)



Pd28-02 an ipod-guided slow breathing intervention to control hot flashes in advanced prostate cancer patients on hormone therapy

Mon, 28 Mar 2016 19:24:10 +0100

The purpose of this study is to determine the feasibility and efficacy of a breathing technique, guided by an iPod Touch® application, to manage hot flashes among prostate cancer (PC) survivors after experiencing a rising PSA. Androgen deprivation therapy (ADT) is considered first-line treatment for this patient population. Although effective in slowing the rise in PSA, ADT has side effects, such as vasomotor symptoms (VS; also known as hot flashes). Up to 50% of men report VS severe enough to require treatment. (Source: The Journal of Urology)



Mp50-08 can angiotensin-converting enzyme inhibitors reduce the incidence, severity, and duration of radiation proctitis?

Mon, 28 Mar 2016 19:24:09 +0100

To determine whether participants taking angiotensin-converting enzyme inhibitors (ACEIs) and treated with radical radiation therapy with neoadjuvant/adjuvant hormone therapy have less incidence, severity, and duration of radiation proctitis. (Source: The Journal of Urology)



Pd43-11 adjuvant maximum androgen blockage compared with bicalutamide 150mg in patients with localized high-risk prostate cancer after radical prostatectomy

Mon, 28 Mar 2016 19:24:04 +0100

The role of adjuvant hormonal therapy and optimized regimens for high-risk localized prostate cancer (PCa) after radical prostatectomy (RP) remains controversial. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp09-14 external validation of a model predicting survival of men with recurrent prostate cancer after radical prostatectomy

Mon, 28 Mar 2016 19:24:02 +0100

The aim of this study was to develop and externally validate a novel model aimed at predicting cancer-specific mortality (CSM) after biochemical recurrence (BCR) among prostate cancer (PCa) patients treated with radical prostatectomy (RP) with or without adjuvant external beam radiotherapy (aRT) and/or hormonal therapy (aHT). (Source: The Journal of Urology)



Mp18-05 is salvage focal cryotherapy curative treatment for patients with localized recurrent prostate cancer?

Mon, 28 Mar 2016 19:24:01 +0100

The salvage therapy options for patients with recurrent unilateral prostate cancer after primary radiation, or cryotherapy are limited. Salvage focal cryotherapy is becoming a more popular treatment option as it has shown success in its disease free survival rates. Salvage focal cryotherapy enables patients to delay or negate the use of hormone therapy which has many unfavorable adverse effects. The aim of this study is to report on the curative success of salvage focal cryotherapy in recurrent unilateral prostate cancer patients. (Source: The Journal of Urology)



Mp90-15 galectin-3 is implicated in the progression of castration-resistant prostate cancer through the regulation of angiogenesis and androgen receptor signaling

Mon, 28 Mar 2016 19:24:01 +0100

Castration-resistant prostate cancer (CRPC) has been common and is the leading cause of prostate cancer death at present. Therefore, to clarify the mechanism of resistance to hormone therapy is useful for the new strategy of treatment for CRPC. Galectin-3 has been shown to be correlated with tumor progression and metastasis in a variety of cancer cells through the regulation of cell proliferation, invasion, angiogenesis, and apoptosis. Here, we investigate the effects and mechanisms of galectin-3 on the tumor progression and hormone resistance for CRPC. (Source: The Journal of Urology)



Mp14-10 detrimental role of pre-prostatectomy neoadjuvant androgen deprivation in node-negative patients treated with adjuvant rt

Mon, 28 Mar 2016 19:24:01 +0100

To investigate a possible detrimental role of neoadjuvant hormonal therapy (NEOHT) prior to radical prostatctomy (RP) in a cohort of 513 node-negative patients (pts) treated with RP and adjuvant radiotherapy (ART) followed for more than 10 years. (Source: The Journal of Urology)



Current Strategies and Future Directions in Classification and Treatment of Uterine Sarcomas

Mon, 28 Mar 2016 12:30:44 +0100

Uterine sarcomas comprise endometrial stroma tumors (EST) and uterine leiomyosarcomas (ULMS), with ESTs accounting for less than 2% and ULMS accounting for approximately 1% of uterine neoplasms. Recent classifications of ESTs denote as many as four categories: benign endometrial stromal nodule (ESN), low-grade endometrial stromal sarcomas (ESS), high-grade endometrial stromal sarcomas (HGESS), and undifferentiated uterine sarcomas (UUS). The designation UUS has been suggested to encompass undifferentiated endometrial sarcomas (UES) and undifferentiated uterine sarcomas of other tissue origins. The prognosis for ESS is good. Although a third of cases recur, the 5-year survival rate for Stage I disease can be as high as 98%. In contrast the prognosis for UES is poor, with a 5-year survival r...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Stopping systemic menopausal hormone therapy: Why, when and how

Wed, 23 Mar 2016 23:00:00 +0100

(Source: Maturitas)



Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery

Wed, 23 Mar 2016 00:15:31 +0100

Conclusions: Patients diagnosed with PCa with LNI who were treated with RT with or without a prior surgery had relatively favorable long-term outcomes. (Source: American Journal of Clinical Oncology)



MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer

Tue, 22 Mar 2016 23:00:00 +0100

Publication date: 15 April 2016 Source:Life Sciences, Volume 151 Author(s): Amin Isanejad, Ali Mohammad Alizadeh, Sadegh Amani Shalamzari, Hamid Khodayari, Saeed Khodayari, Vahid Khori, Najmeh Khojastehnjad Aims MicroRNAs (miRNAs) are the targeting signal-transduction pathways that can mediate tumorigenesis via their down and/or up-regulation. For example, miR-21 and miR-206 can effect on the tumor angiogenesis as an oncomir and a tumor suppressor, respectively. Materials and methods The present study is aimed to investigate the effects of the interval exercise training in combination with tamoxifen and/or letrozole on miR-21, miR-206 and let-7 as well as their underlying pathways in regard to tumor angiogenesis in sixty four mice with breast tumor. ELISA, immunohistochemistry, q...



Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO SPECIAL ARTICLE]

Tue, 22 Mar 2016 23:00:00 +0100

Purpose To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. Methods A literature search and prospectively defined study selection sought systematic reviews, meta-analyses, randomized controlled trials, prospective-retrospective studies, and prospective comparative observational studies published from 2006 through 2014. Outcomes of interest included overall survival and disease-free or recurrence-free survival. Expert panel members used informal consensus to develop evidence-based guideline recommendations. Results The literature search identified 50 relevant studies. One randomized clinical trial and 18 prospective-retrospective studies were found to have e...



Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen

Mon, 21 Mar 2016 23:00:00 +0100

We examined the association of oral BP use on risk of contralateral breast cancer (CBC) and recurrence in 16,781 women diagnosed with early-stage breast cancer from 1996 to 2007, treated with tamoxifen, and followed through December 31, 2009 at Kaiser Permanente Northern California (KPNC, n = 8857) and Southern California (KPSC, n = 7924). Sociodemographic, clinical, and pharmacy information were extracted from electronic medical records and cancer registries. CBC was identified from cancer registries, and recurrences from electronic health records and chart reviews. Multivariate Cox regression models were used to estimate hazard ratios (HR) and 95 % confidence intervals (CI) treating BP use and hormonal therapy as time-varying variables. After mean 6.4 years of follow-up, 494 (3.0 ...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Estrogen turns down “the AIRE”

Mon, 21 Mar 2016 20:22:02 +0100

Genetic alterations are known drivers of autoimmune disease; however, there is a much higher incidence of autoimmunity in women, implicating sex-specific factors in disease development. The autoimmune regulator (AIRE) gene contributes to the maintenance of central tolerance, and complete loss of AIRE function results in the development of autoimmune polyendocrinopathy syndrome type 1. In this issue of the JCI, Dragin and colleagues demonstrate that AIRE expression is downregulated in females as the result of estrogen-mediated alterations at the AIRE promoter. The association between estrogen and reduction of AIRE may at least partially account for the elevated incidence of autoimmune disease in women and has potential implications for sex hormone therapy. (Source: Journal of Clinical Inves...



GPs could initiate hormone therapy for transgender patients, says GMC

Mon, 21 Mar 2016 10:46:59 +0100

GPs should consider prescribing 'bridging' hormone treatment to transgender patients attempting to self-medicate while they await specialised gender identity treatment, GMC guidance recommends. (Source: GP Online News)



Effective treatment of gastrointestinal bleeding with thalidomide - Chances and limitations.

Sun, 20 Mar 2016 23:00:00 +0100

Authors: Bauditz J Abstract For more than 50 years bleeding from gastrointestinal angiodysplasias has been treated by hormonal therapy with estrogens and progesterons. After a randomized study finally demonstrated that hormones have no effect on bleeding events and transfusion requirements, therapy has switched to endoscopic coagulation. However, angiodysplasias tend to recur over months to years and endoscopy often has to be repeated for long time periods. Thalidomide, which caused severe deformities in newborn children in the 1960s, is now increasingly used after it was shown to suppress tumor necrosis factor alpha, inhibit angiogenesis and to be also effective for treatment of multiple myeloma. In 2011 thalidomide was proven to be highly effective for treatment of bleeding from ...



Treatment trends for clinically localized prostate cancer. National population analysis: GESCAP group

Sat, 19 Mar 2016 00:00:00 +0100

Conclusions This is the first national European study to evaluate the therapeutic management of localized PC based on the risk group to which the patient belonged. Most young patients (≤65 years) with low-intermediate risk localized PC were treated with surgery, which adheres to the recommendations of the 2010 UAE guidelines. Various therapeutic combinations have been employed for patients with high-risk, locally advanced localized tumors, revealing the need for a multidisciplinary approach (Controlled-trials.com number: ISRCTN19893319). (Source: Actas Urologicas Espanolas)



Significance of erection hardness score as a diagnostic tool to assess erectile function recovery in Japanese men after robot-assisted radical prostatectomy

Fri, 18 Mar 2016 23:00:00 +0100

This study prospectively included 170 Japanese patients with localized prostate cancer (PC) undergoing RARP without neoadjuvant hormonal therapy. The erectile function of each patient was assessed based on the International Index of Erectile Function-5 (IIEF-5) and EHS at the baseline and on every visit to an outpatient clinic after RARP. In this series, potency was defined as the ability to have an erection sufficient for intercourse, corresponding to EHS ≥3, while patients with EHS ≥2 were regarded as those with erectile function. Of these 170 patients, 20 and 75 underwent bilateral and unilateral nerve-sparing procedures, respectively; however, non-nerve-sparing procedures were performed in the remaining 75. A proportional increase in the IIEF-5 score according to EHS was noted at 2...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




[Comment] Defining new standards of care for men with prostate cancer

Fri, 18 Mar 2016 22:34:04 +0100

Improving the outcomes of medical or surgical castration for men with prostate cancer has been an elusive goal since the approach was first reported in the 1940s.1 However, this situation changed at the annual American Society of Clinical Oncology meeting in 2014, when results reported from the ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease (CHAARTED) showed that addition of six cycles of docetaxel to standard of care (testosterone lowering hormone therapy) prolonged the survival of men with metastatic disease at the time of diagnosis relative to treatment with hormones alone. (Source: LANCET)



Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use

Thu, 17 Mar 2016 00:00:00 +0100

Women receiving vitamin K antagonists (VKAs) require adequate contraception because of the potential for fetal complications. It is unknown whether the use of hormonal therapy, especially those containing estrogens, is associated with recurrent venous thromboembolism (VTE) during anticoagulation. Despite the absence of data, World Health Organization guidelines state that use of estrogen-containing contraceptives confers an "unacceptable health risk" during established anticoagulation for VTE. We compared the incidences of recurrent VTE and abnormal uterine bleeding with and without concomitant hormonal therapy in women aged <60 years who were receiving anticoagulation with rivaroxaban or enoxaparin/VKA for confirmed VTE. Incidence densities in percentage per year were computed for the ...



Breast carcinoma and phyllodes tumour: a case series

Thu, 17 Mar 2016 00:00:00 +0100

We report the clinicopathological characteristics of in situ and invasive carcinoma coexisting with PT in 10 patients treated in our institution over an 11-year period from 1992 to 2012. Ten patients with coexisting PT and in situ or invasive carcinoma were identified from our records. Six had carcinoma found within the PT. All were female with a median age of 47 (43–72) years. One patient had a history of PT in the same breast while another had a history of PT in the same breast as well as invasive ductal carcinoma in the contralateral breast. The rest did not have any risk factors of breast cancer. Five patients had a preoperative core needle biopsy performed with the report of a fibroepithelial lesion. The rest of the patients had surgery upfront for their breast masses. Two patie...



Long-term hormonal therapy benefits men with locally advanced prostate cancer

Wed, 16 Mar 2016 13:05:28 +0100

Hormonal therapy, also known as androgen-deprivation therapy, can be a powerful weapon in the fight against prostate cancer because it deprives malignant cells of the fuel they need to grow. Androgens — meaning the family of male sex hormones that includes testosterone — contribute to physical characteristics such as a deeper voice, thick facial hair, and increased muscle strength and bone mass. But when prostate cancer develops, testosterone also contributes to tumor growth and progression. Depending on the specific treatment used, hormonal therapy can either stop the body from making testosterone or prevent it from interacting with cancer cells. Though it was once reserved solely for treating prostate cancer that has spread, doctors now also combine hormonal therapy with radiation to...



Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype.

Tue, 15 Mar 2016 14:38:02 +0100

Authors: Rettberg JR, Dang H, Hodis HN, Henderson VW, St John JA, Mack WJ, Brinton RD Abstract Detecting at-risk individuals within a healthy population is critical for preventing or delaying Alzheimer's disease. Systems biology integration of brain and body metabolism enables peripheral metabolic biomarkers to serve as reporters of brain bioenergetic status. Using clinical metabolic data derived from healthy postmenopausal women in the Early versus Late Intervention Trial with Estradiol (ELITE), we conducted principal components and k-means clustering analyses of 9 biomarkers to define metabolic phenotypes. Metabolic clusters were correlated with cognitive performance and analyzed for change over 5 years. Metabolic biomarkers at baseline generated 3 clusters, representing women w...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Obesity, Oral Contraceptive Use, and Cerebral Venous Thrombosis

Tue, 15 Mar 2016 00:00:00 +0100

Cerebral venous thrombosis (CVT) is an uncommon cause of stroke that primarily affects young adults. A unique risk factor profile and plurality of presenting features make it an elusive diagnosis unless a high index of suspicion is maintained. It comprises approximately 0.5% to 1% of all strokes, and widespread availability of magnetic resonance imaging has made recognition easier. The International Study on Cerebral Vein and Dural Sinus Thrombosis is the largest prospective, multinational, observational study of patients with CVT to date, including 624 consecutive patients with symptomatic CVT at 89 centers between May 1998 and May 2001. Of these patients, 465 were women (74.5%), and they tended to be younger than men at diagnosis (median age, 34 vs 42 years). A total of 301 (65.0%) of ...



Vaginal estradiol use and the risk for cardiovascular mortality

Tue, 15 Mar 2016 00:00:00 +0100

STUDY QUESTION Does the use of post-menopausal vaginal estradiol (VE) affect the mortality risk for coronary heart disease (CHD) and stroke. SUMMARY ANSWER The use of VE reduces the risk for cardiovascular mortality. WHAT IS KNOWN ALREADY A growing number of women use VE for post-menopausal genitourinary symptoms. Although this therapy is intended to have only local effects, estrogen is absorbed into the blood circulation and thus VE use may also have systemic effects. STUDY DESIGN, SIZE, DURATION We studied a nationwide cohort in Finland 1994–2009 during which post-menopausal women (n = 195 756) initiated the use of VE (age [mean ± SD] 65.7 ± 10.9 years). Follow-up data gathered 1.4 million women-years and we assessed the mortality risk due to CHD (n= 9656) or strok...



Chinese herbal medicine for menopausal symptoms.

Tue, 15 Mar 2016 00:00:00 +0100

CONCLUSIONS: We found insufficient evidence that Chinese herbal medicines were any more or less effective than placebo or HT for the relief of vasomotor symptoms. Effects on safety were inconclusive. The quality of the evidence ranged from very low to moderate; there is a need for well-designed randomised controlled studies. PMID: 26976671 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)



Male Prison Inmates With Gender Dysphoria: When Is Sex Reassignment Surgery Appropriate?

Tue, 15 Mar 2016 00:00:00 +0100

Authors: Osborne CS, Lawrence AA Abstract Gender dysphoria (GD), a feeling of persistent discomfort with one's biologic sex or assigned gender, is estimated to be more prevalent in male prison inmates than in nonincarcerated males; there may be 3000-4000 male inmates with GD in prisons in the United States. An increasing number of U.S. prison systems now offer gender dysphoric inmates diagnostic evaluation, psychotherapy, cross-sex hormone therapy, and opportunities, albeit limited, to enact their preferred gender role. Sex reassignment surgery (SRS), however, has not been offered to inmates except in response to litigation. In the first case of its kind, the California Department of Corrections and Rehabilitation recently agreed to provide SRS to an inmate and developed policy gui...



The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio

Mon, 14 Mar 2016 00:00:00 +0100

Conclusions: NMR was associated with 1-week smoking abstinence; NMR may be a useful addition to medication screening approaches evaluating treatments for nicotine dependence. (Source: Nicotine and Tobacco Research)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Hormone use and stroke

Mon, 14 Mar 2016 00:00:00 +0100

Publication date: Available online 14 March 2016 Source:Apollo Medicine Author(s): Pushpendra Nath Renjen, Dinesh M. Chaudhari, Mahir Meman Strokes are an important cause of disability and death among older women. Because many women use hormone therapy for the control of perimenopausal symptoms and to prevent osteoporosis after menopause, establishing whether such therapy has other health effects is of considerable clinical importance. Overall, 55% of strokes occur in women, and women account for nearly 60% of all stroke-related deaths. Women appear to be protected from heart disease and stroke before menopause. This is thought to be because of the protective effects of ovarian hormones, and this effect could provide clues on new paradigms to prevent stroke and ischemic vascular disea...



Salvage hormonal therapy after failed microdissection testicular sperm extraction: A multi‐institutional prospective study

Mon, 14 Mar 2016 00:00:00 +0100

ConclusionsEffectiveness of human chorionic gonadotropin‐based salvage hormonal therapy preceding a second microdissection testicular sperm extraction seems to be limited. Non‐obstructive azoospermia men who have differentiated cells in their testes are likely to respond to hormonal stimulation. (Source: International Journal of Urology)



Medical News Today: Multi-gene test identifies early breast cancer that may be spared chemo

Fri, 11 Mar 2016 11:00:00 +0100

A multi-gene test that identifies early breast cancer patients who can be treated with anti-hormonal therapy alone and no chemotherapy has shown successful results in a trial. (Source: Health News from Medical News Today)



Growth Hormone Deficiency in Prepubertal Children: Predictive Markers of Cardiovascular Disease

Wed, 09 Mar 2016 15:22:17 +0100

Background: Cardiovascular (CV) risk factors have been identified in adults with untreated growth hormone deficiency (GHD). Existing evidence suggests that the development of the atheromatous plaque begins early in childhood. Previous reports have shown that GHD children are prone to increased CV risks including impaired cardiac function, dyslipidemia and abnormalities in body composition. Recent studies in epigenetics and metabolomics have defined specific fingerprints that might be associated with an increased risk of CV disease. Aim: The aim of this review is to point out the most significant biochemical and clinical predictive markers of CV disease in prepubertal children and to evaluate the effect of recombinant human growth hormone therapy on most of these alterations. The novel find...



Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies [EDITORIALS]

Wed, 09 Mar 2016 00:00:00 +0100

(Source: Journal of Clinical Oncology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V [Breast Cancer]

Wed, 09 Mar 2016 00:00:00 +0100

Conclusion Patients with ER-positive breast cancer maintain a significant recurrence rate during extended follow up. Strategies for follow up and treatments to prevent recurrences may be most efficiently applied and studied in patients with ER-positive disease followed for a long period of time. (Source: Journal of Clinical Oncology)






Hormones, From Puberty to Post-Menopause

Tue, 08 Mar 2016 22:14:31 +0100

By The Society For Women's Health Research If you're a woman, you probably know that our bodies go through myriad changes during the course of our lives. Hormones play an integral role in those changes at each stage of development, from puberty to post-menopause. This is the first in a four-part series the Society For Women's Health Research (SWHR®)will be publishing about hormones across the lifespan -- read on to learn more! What exactly are hormones? The Virginia Women's Center offers a good definition: A hormone is a "chemical communicator or connector" that carries messages to and from all the organs in the body. A hormone acts like a key that fits into a specific lock or receptor site at each organ. This inter-organ communication helps the body to remain balanced and function optim...



Talc and ovarian cancer: what the most recent evidence shows

Tue, 08 Mar 2016 10:30:00 +0100

Conclusion This case-control study aimed to investigate the association between talc use and ovarian cancer. The researchers found a significant link between genital talc use and ovarian cancer – an increase in risk of a third, compared with no use. However, the study has important limitations and is not able to prove direct cause and effect. Although this was a case-control study that made use of data collected as part of an ongoing cohort study, talc use only seems to have been assessed after cancer diagnosis.  The study says that, "subjects were personally interviewed about potential ovarian cancer risk factors that occurred more than one year before diagnosis". There is therefore a possibility that women recalled their talc use inaccurately, leading to misclassification...



Where Prostate Cancer Spreads In the Body Affects Survival Time

Tue, 08 Mar 2016 08:16:45 +0100

Contact: Sarah Avery Phone: 919-660-1306 Email: sarah.avery@duke.edu https://www.dukehealth.org EMBARGOED FOR RELEASE until 4 p.m. (ET) on Monday, March 7, 2016 DURHAM, N.C. -- Patients with lymph-only metastasis have the longest overall survival, while those with liver involvement fare worst. Lung and bone metastasis fall in the middle. “Smaller studies had given doctors and patients indications that the site of metastasis in prostate cancer affects survival, but prevalence rates in organ sites were small, so it was difficult to provide good guidance,” said Susan Halabi, Ph.D., professor of biostatistics at Duke and lead author of the study published online March 7 in the Journal of Clinical Oncology. “With the large numbers we analyzed in our study, we were able to compare all of ...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Your NEJM Group Today: Menopause Management, Guanfacine & ADHD, Montana Internist & Hospitalist Opportunities (FREE)

Tue, 08 Mar 2016 00:00:00 +0100

By the Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today:NEJM Clinical Practice Center: Perspective: Use of systemic hormone therapy … (Source: Physician's First Watch current issue)



Pharmacotherapy considerations in the management of transgender patients: an alternative viewpoint

Tue, 08 Mar 2016 00:00:00 +0100

This article is protected by copyright. All rights reserved. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)



C/EBPβ regulates sensitivity to bortezomib in prostate cancer cells by inducing and autophagosome–lysosome fusion

Tue, 08 Mar 2016 00:00:00 +0100

Metastatic prostate cancer (PCa) is an incurable disease and a leading cause of cancer death in Europe and North America. When patients acquire resistance to hormonal therapy, second-line chemotherapy is administered, which can increase patient life span by several years. There has been interest in the use of bortezomib, a proteasome inhibitor, for the treatment of PCa, but clinical studies have shown only modest or no significant improvement in patient benefit when administered in combination with hormonal therapy or docetaxel [1–3]. (Source: Cancer Letters)



[Combined radiation therapy and androgen deprivation in the management of prostate cancer: Where do we stand?]

Tue, 08 Mar 2016 00:00:00 +0100

Authors: Bellefqih S, Hadadi K, Mezouri I, Maghous A, Marnouche E, Andaloussi K, Elmarjany M, Sifat H, Mansouri H, Benjaafar N Abstract Radiotherapy and androgen deprivation therapy play a major role in the management of prostate cancer. Indeed, radiotherapy and hormone therapy are combined in a neoadjuvant and concomitant setting for intermediate risk cancers but also in an adjuvant setting in high risk or locally advanced prostate cancer. The benefice of this association was suggested by preclinical studies and demonstrated later by several randomized trials. However, as these trials were conducted before the era of dose escalation the role of androgen deprivation therapy in this case is less clear. Moreover, as hormonal therapy can lead to a significant morbidity and a decrement...



C/EBPβ regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome–lysosome fusion

Tue, 08 Mar 2016 00:00:00 +0100

Metastatic prostate cancer (PCa) is an incurable disease and a leading cause of cancer death in Europe and North America. When patients acquire resistance to hormonal therapy, second-line chemotherapy is administered, which can increase patient life span by several years. There has been interest in the use of bortezomib, a proteasome inhibitor, for the treatment of PCa, but clinical studies have shown only modest or no significant improvement in patient benefit when administered in combination with hormonal therapy or docetaxel [1–3]. (Source: Cancer Letters)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




13: Genetic determinants of pelvic organ prolapse in women of european american descent: The women’s health initiative

Sun, 06 Mar 2016 18:07:21 +0100

Approximately 3-5% of U.S. women are affected by pelvic organ prolapse (POP), with European American women (EA) at particularly high risk. Recent evidence suggests a moderate genetic predisposition to POP, yet very few genetic loci have been identified. Thus, we used validated measurements of POP from the Women’s Health Initiative (WHI) Hormone Therapy (HT) trial and extant genome wide genotyping data to perform a genome wide association study (GWAS) of POP in European American (EA) study participants. (Source: American Journal of Obstetrics and Gynecology)



Managing Menopause: Cutting Through the ConfusionManaging Menopause: Cutting Through the Confusion

Thu, 03 Mar 2016 17:07:31 +0100

Dr JoAnn Manson clarifies misunderstandings about the use of hormone therapy for postmenopausal women. Medscape Ob/Gyn (Source: Medscape FamilyMedicine Headlines)



Managing Menopause: Are the WHI Results Being Misunderstood?Managing Menopause: Are the WHI Results Being Misunderstood?

Thu, 03 Mar 2016 16:07:39 +0100

Dr JoAnn Manson clarifies misunderstandings about the use of hormone therapy for postmenopausal women. Medscape Ob/Gyn (Source: Medscape ObGyn and Womens Health Headlines)



Age-related differences in persistence with bisphosphonates in women with metastatic breast cancer

Thu, 03 Mar 2016 00:00:00 +0100

Conclusions Women with metastatic BC aged >70 are at a lower risk of BIS treatment discontinuation than younger women. (Source: Journal of Bone Oncology)



Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study [Treatment-Related Complications]

Wed, 02 Mar 2016 00:00:00 +0100

Conclusion Attention should be given to the increased symptom burden associated with ET, and better efforts should be made to address patient-reported outcomes. (Source: Journal of Clinical Oncology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Influence of thyroid hormone therapy on the fracture rate – a claims data cohort study

Wed, 02 Mar 2016 00:00:00 +0100

It has been debated for years whether long-term thyroid hormone intake causes fractures. Not only have previous studies suffered from design limitations, they also reached contradictory conclusions. We investigated thyroid hormones (thyroxine) as a possible risk factor for fractures in a cohort of 6.7 million persons based on administrative data. (Source: Bone)



Flavonoid intake and incident hypertension in women.

Wed, 02 Mar 2016 00:00:00 +0100

CONCLUSION: In this large prospective cohort of French middle-aged women, participants with greater flavonol, anthocyanin, and polymeric flavonoid intakes and greater total flavonoid intake were less likely to develop hypertension. PMID: 26936332 [PubMed - as supplied by publisher] (Source: The American Journal of Clinical Nutrition)



Influence of thyroid hormone therapy on the fracture rate — A claims data cohort study

Wed, 02 Mar 2016 00:00:00 +0100

It has been debated for years whether long-term thyroid hormone intake causes fractures. Not only have previous studies suffered from design limitations, they also reached contradictory conclusions. We investigated thyroid hormones (thyroxine) as a possible risk factor for fractures in a cohort of 6.7 million persons based on administrative data. (Source: Bone)



The molecular actions of oestrogen in the regulation of vascular health

Tue, 01 Mar 2016 00:00:00 +0100

New Findings What is the topic of this review? This review summarizes the beneficial actions of oestrogen on the vasculature, highlighting both molecular mechanisms and functional outcomes. What advances does it highlight? The net effect of oestrogen on the vascular health of women continues to be debated. Recent advances have provided strong evidence for the role of membrane‐bound oestrogen receptors in the maintenance of normal endothelial function. On a broader scale, functional outcomes of oestrogen actions on the vasculature may mediate the reduced risk of cardiovascular disease in premenopausal women. The conflicting implications of the large‐scale clinical menopausal hormone therapy trials in humans versus the findings of studies on experimental animals underscore the limita...



Chronic Pelvic Pain in Women.

Tue, 01 Mar 2016 00:00:00 +0100

Authors: Speer LM, Mushkbar S, Erbele T Abstract Chronic pelvic pain in women is defined as persistent, noncyclic pain perceived to be in structures related to the pelvis and lasting more than six months. Often no specific etiology can be identified, and it can be conceptualized as a chronic regional pain syndrome or functional somatic pain syndrome. It is typically associated with other functional somatic pain syndromes (e.g., irritable bowel syndrome, nonspecific chronic fatigue syndrome) and mental health disorders (e.g., posttraumatic stress disorder, depression). Diagnosis is based on findings from the history and physical examination. Pelvic ultrasonography is indicated to rule out anatomic abnormalities. Referral for diagnostic evaluation of endometriosis by laparoscopy is u...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Expression and Clinical Significance of Serum Dipeptidyl Peptidase IV Chronic Obstructive Pulmonary Disease.

Tue, 01 Mar 2016 00:00:00 +0100

CONCLUSIONS: Serum DPPIV concentration in patients with COPD is decreased significantly, and there is no correlation between serum DPPIV concentration and sex or age. Serum DPPIV not only is an independent predictive factor, but also of high value as a good serologic marker for the diagnosis of COPD. PMID: 26992252 [PubMed - in process] (Source: The American Journal of the Medical Sciences)



ASK THE DOCTOR: Prostate drugs made me pile on the pounds 

Mon, 29 Feb 2016 23:20:17 +0100

Following hormone therapy for prostate cancer in 2011 and radiotherapy in 2012, a reader's waistline has ballooned to 38 in. Dr Scurr advises. (Source: the Mail online | Health)



Hormonal therapy tested in older men

Mon, 29 Feb 2016 17:36:47 +0100

A study suggested that testosterone therapy may improve sexual function for some older men with low levels of the hormone. Other benefits and risks need to be studied further. (Source: NIH Research Matters from the National Institutes of Health (NIH))



Training needed to increase physician comfort level with transgender patients

Mon, 29 Feb 2016 05:00:00 +0100

(George Washington University) George Washington University (GW) Researcher Michael S. Irwig, M.D. published a first-of-its-kind survey assessing the attitudes and practice patterns of transgender care by endocrinologists, who often treat transgender patients with hormone therapy. (Source: EurekAlert! - Social and Behavioral Science)



Incidence and occupational variation of ovarian granulosa cell tumours in Finland, Iceland, Norway and Sweden during 1953–2012: a longitudinal cohort study

Mon, 29 Feb 2016 00:00:00 +0100

ConclusionOur findings support the concept of GCT as a primarily sporadic, not exposure‐related, cancer. Tweetable abstractThe Nordic incidence rates of GCTs show stability over time and among different occupational categories. (Source: BJOG: An International Journal of Obstetrics and Gynaecology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Effects of Hormone Therapy on Intraocular Pressure: The Women’s Health Initiative-Sight Exam Study

Mon, 29 Feb 2016 00:00:00 +0100

Previous studies suggest that hormone therapy favorably affects intraocular pressure (IOP). Here, we examined the association between hormone therapy use and IOP in the context of a large randomized trial. (Source: American Journal of Ophthalmology)



Abstract B08: ESR1 coregulator binding site inhibitors (ECBIs) as novel therapeutics to target hormone therapy-resistant breast cancer

Mon, 29 Feb 2016 00:00:00 +0100

Conclusions: The ECBI is a novel agent that targets ESR1 with a unique mechanism of action. ECBI has distinct pharmacologic advantages of oral bioavailability, in vivo stability, and is associated with minimal systemic side effects. Remarkably, ECBIs block both native and mutant forms of ESR1 and have activity against therapy resistant breast cancer cell proliferation both in vitro and in vivo and against primary human tissues ex vivo. Thus development of ECBI represents a quantum leap in therapies to target ESR1Citation Format: Ratna K. Vadlamudi, Gangadhara Reddy Sareddy, Suryavathi Viswanadhapalli, Tae-Kyung Lee, Shi-Hong Ma, Wan Ru Lee, Monica Mann, Samaya Rajeshwari Krishnan, Vijay Gonugunta, Douglas W. Strand, Rajeshwar Rao Tekmal, JungMo Ahn, Ganesh V. Raj. ESR1 coregulator binding ...



Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition

Sat, 27 Feb 2016 07:21:23 +0100

Conclusions: These data suggest that estradiol variability may enhance emotional sensitivity to psychosocial stress, particularly sensitivity to social rejection. Combined with VSLEs proximate to the menopausal transition, this increased sensitivity may contribute to the development of depressed mood. (Source: Menopause)



Effectiveness of a 2-year menopause medicine curriculum for obstetrics and gynecology residents

Sat, 27 Feb 2016 07:21:23 +0100

Objective: Previous work has shown American obstetrics and gynecology (OB/GYN) residents are lacking in menopause training. Our objective was to assess the effectiveness of a 2-year menopause medicine curriculum in improving OB/GYN residents’ knowledge and self-assessed competency in menopause topics. Methods: We developed a menopause medicine-teaching curriculum for OB/GYN residents at our academic hospital-based residency program. The 2-year curriculum was composed of year 1: four 1-hour lectures and one 2-hour lab with cases presentations, and year 2: three 1-hour lectures and one 2-hour lab. Core topics included menopause physiology, hormone therapy, breast health, bone health, cardiovascular disease, and autoimmune disease. Pre- and posttests assessed resident knowledge and comfort...



Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis

Sat, 27 Feb 2016 07:21:23 +0100

Conclusions: Based on the results of meta-analysis, HT does not influence the odds of ovarian cancer recurrence; however, this conclusion must be confirmed separately because of significant limitations in the methodological quality of the studies included. (Source: Menopause)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Dry eye in postmenopausal women: a hormonal disorder

Sat, 27 Feb 2016 07:21:23 +0100

Conclusions: Because of the high incidence of dry eye among postmenopausal women that may be related to the hormonal treatment, we propose that a multidisciplinary approach should be considered between gynecologists and ophthalmologists in management of this disorder. (Source: Menopause)



Priorities for transgender medical and healthcare research

Sat, 27 Feb 2016 02:35:24 +0100

Purpose of review: Transgender individuals experience unique health disparities but are the subject of little focused health research. This manuscript reviews current literature on transgender medical and mental health outcomes and proposes research priorities to address knowledge gaps. Recent findings: Published research in transgender healthcare consists primarily of case reports, retrospective and cross-sectional studies, involving largely European settings. Challenges to US-based transgender health research include a diverse population where no single center has sufficient patient base to conduct clinical research with statistical rigor. Treatment regimens are heterogeneous and warrant study for best practices. Current research suggests increased mortality and depression in transgende...



Male Breast Cancer, clinical presentation, diagnosis and treatment: twenty years of experience in our Breast Unit.

Sat, 27 Feb 2016 00:00:00 +0100

Conclusion the male breast cancer has many similarities to breast cancer in women, but there are distinct functions that need to be appreciated. Future research for a better understanding of the disease should provide a better account of genetic and epigenetic characteristics of these forms; but, above all, epidemiological and biological cohorts numerically more consistent. (Source: International Journal of Surgery Case Reports)



MicroRNA-206, Let-7 and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer

Sat, 27 Feb 2016 00:00:00 +0100

Publication date: Available online 26 February 2016 Source:Life Sciences Author(s): Amin Isanejad, Ali Mohammad Alizadeh, Sadegh Amani Shalamzari, Hamid Khodayari, Saeed Khodayari, Vahid Khori, Najmeh Khojastehnjad Aims MicroRNAs (miRNAs) are the targeting signal-transduction pathways that can mediate tumorigenesis via their down and/or up-regulation. For example, miR-21 and miR-206 can effect on the tumor angiogenesis as an oncomir and a tumor suppressor, respectively. Materials and methods The present study is aimed to investigate the effects of the interval exercise training in combination with tamoxifen and/or letrozole on miR-21, miR-206 and let-7 as well as their underlying pathways in regard to tumor angiogenesis in sixty four mice with breast tumor. ELISA, immunohistochem...



Personal and professional use of menopausal hormone therapy among gynecologists: A multinational study (REDLINC VII)

Sat, 27 Feb 2016 00:00:00 +0100

(Source: Maturitas)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Medication use by early-stage breast cancer survivors: a 1-year longitudinal study

Thu, 25 Feb 2016 10:35:12 +0100

Conclusions There is an increase in trend of chronic medication usage in breast cancer survivors after cancer treatment. This study provides important insights into the design of medication management programs tailored to this population. Future studies should incorporate a control population to improve the interpretation of study results. (Source: Supportive Care in Cancer)



Committee Opinion No. 659: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer.

Wed, 24 Feb 2016 14:25:03 +0100

Authors: Abstract Cancer treatment should address female-specific survivorship issues, including the hypoestrogenic- related adverse effects of cancer therapies or of natural menopause in survivors. Systemic and vaginal estrogen are widely used for symptomatic relief of vasomotor symptoms, sexual dysfunction, and lower urinary tract infections in the general population. However, given that some types of cancer are hormone sensitive, there are safety concerns about the use of local hormone therapy in women who currently have breast cancer or have a history of breast cancer. Nonhormonal approaches are the first-line choices for managing urogenital symptoms or atrophy-related urinary symptoms experienced by women during or after treatment for breast cancer. Among women with a history...



Committee Opinion No. 659 Summary: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer.

Wed, 24 Feb 2016 14:25:03 +0100

Authors: Abstract Cancer treatment should address female-specific survivorship issues, including the hypoestrogenic- related adverse effects of cancer therapies or of natural menopause in survivors. Systemic and vaginal estrogen are widely used for symptomatic relief of vasomotor symptoms, sexual dysfunction, and lower urinary tract infections in the general population. However, given that some types of cancer are hormone sensitive, there are safety concerns about the use of local hormone therapy in women who currently have breast cancer or have a history of breast cancer. Nonhormonal approaches are the first-line choices for managing urogenital symptoms or atrophy-related urinary symptoms experienced by women during or after treatment for breast cancer. Among women with a history...



Progesterone hormone therapy to prevent premature births 'does not work', researchers claim

Wed, 24 Feb 2016 12:00:00 +0100

Research by scientists in Edinburgh, published in The Lancet, found that treatment with progesterone made no difference to premature birth rates. The Mirror (Source: Society for Endocrinology)



Male, Female, Other: Transgender and the Impact in Primary Care

Wed, 24 Feb 2016 00:00:00 +0100

In this study we discuss the transgender patient and outline basic care and issues that can arise in a primary care setting. (Source: The Journal for Nurse Practitioners)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts

Tue, 23 Feb 2016 00:00:00 +0100

Abstract Signal transducer and activator of transcription (STAT) transcription factors family are involved in diverse cellular biological functions. Reports regarding the prognostic impact of STAT3 expression in breast cancer (BC) are variable whether being a factor of poor or good prognosis. Immunohistochemical expression of phospho-STAT3 (pSTAT3) was studied in large series of invasive BC (n = 1270). pSTAT3 and STAT3 were quantified using reverse phase protein array (RPPA) on proteins extracted from macro-dissected FFPE tissues (n = 49 cases). STAT3 gene expression in the METABRIC cohort was also investigated. STAT3 gene expression prognostic impact was externally validated using the online BC gene expression data (n = 26 datasets, 4.177 patients). pSTAT3 wa...



Novel physical activity interventions for older patients with prostate cancer on hormone therapy: A pilot randomized study

Tue, 23 Feb 2016 00:00:00 +0100

Conclusions A home-based aerobic and resistance exercise program, EXCAP, shows promise for improving PP in older men with PC on ADT. (Source: Journal of Geriatric Oncology)



Surgery and hormone therapy trends in octogenarians with invasive breast cancer

Tue, 23 Feb 2016 00:00:00 +0100

Conclusions There has been an increase over time in primary nonoperative management of ER+ breast cancer in octogenarians. (Source: The American Journal of Surgery)



Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer

Tue, 23 Feb 2016 00:00:00 +0100

Abstract While androgen ablation remains a mainstay for advanced prostate cancer therapy, nearly all patients will inevitably develop disease escape with time. Upon the development of castration-resistant prostate cancer, other androgen-axis-targeted treatments may be added in an effort to starve the disease of its androgen signaling. Nevertheless, additional androgen-pathway resistance usually develops to these novel hormonal therapies. In this review, we will discuss the resistance mechanisms to modern androgen-axis modulators and how these alterations can influence a patient’s response to novel hormonal therapy. We conceptualize these resistance pathways as three broad categories: (1) reactivation of androgen/AR-signaling, (2) AR bypass pathways, and (3) androgen/AR-independ...



Parity and Components of the Metabolic Syndrome Among US Hispanic/Latina Women: Results From the Hispanic Community Health Study/Study of Latinos [Original Articles]

Tue, 23 Feb 2016 00:00:00 +0100

Conclusions— Higher parity is associated with an increased prevalence of selected components of the metabolic syndrome among Hispanic/Latina women in the US. High parity among Hispanics/Latinas with a high prevalence of abdominal obesity suggests high risk for metabolic dysregulation. (Source: Circulation: Cardiovascular Quality and Outcomes)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Testosterone Replacement Shows Modest Benefits for Depression and Mood

Mon, 22 Feb 2016 19:31:00 +0100

In addition to improving sexual and physical function, testosterone-replacement therapy may decrease depressive symptoms and improve mood in older men with low testosterone levels, according to a study in the New England Journal of Medicine.A total of 790 men 65 years and older with a serum testosterone concentration of less than 275 ng per deciliter were randomly assigned to receive testosterone gel or placebo gel for 1 year. Each man participated in one or more of three trials—the Sexual Function Trial, the Physical Function Trial, and the Vitality Trial; the latter trial included assessments of fatigue, positive and negative mood symptoms (as measured by the Positive and Negative Affect Scale, or PANAS), and depression level (measured by Patient Health Questionnaire 9, or PHQ-9) after...



A systematic review and meta-analysis of comparative studies assessing the efficacy of luteinizing hormone-releasing hormone therapy for children with cryptorchidism

Mon, 22 Feb 2016 00:00:00 +0100

Conclusions LHRH had significant benefits on testicular descent, particularly for inguinal and pre-scrotal testes, which was also accompanied by temporary slight side effects. (Source: International Urology and Nephrology)



Metformin may protect nondiabetic breast cancer women from metastasis

Mon, 22 Feb 2016 00:00:00 +0100

Abstract Metformin, a widely prescribed oral hypoglycemic agent, has recently received a big interest because of its potential antitumorigenic effects in different cancer types. The present study investigated the impact of adding metformin to breast cancer adjuvant therapy in nondiabetic women on, insulin like growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), insulin, fasting blood glucose (FBG), the molar ratio of IGF-1 to IGFBP-3, homeostatic model assessment of insulin resistance (HOMA-IR) and metastasis. 102 women with newly diagnosed breast cancer were divided into 2 main groups, a control group and a metformin group. All women were treated with adjuvant therapy, according to the protocols of Ministry of Health and Population and National Cancer Institute, Egypt. More...



mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials.

Sun, 21 Feb 2016 01:39:02 +0100

Authors: Saveria Rotundo M, Galeano T, Tassone P, Tagliaferri P Abstract We evaluated if standard hormonal therapy (HT) could be improved by the addition of mammalian target of rapamycin inhibitors (mTOR-I) in metastatic luminal breast cancer. A meta-analysis on 4 phase II-III randomized clinical trials was performed. Pooled hazard ratio (HR) for progression free survival (PFS)/ time to progression (TTP) was 0.62 in favor of mTOR-I+HT arm (95% confidence interval [CI] 0.55-0.70; p<0.0001). There was significant heterogeneity for PFS/TTP (Cochran's Q 32, p<0.0001, I2 index 90.6%). Pooled HR for overall survival (OS) was 0.84 in favor of the combination arm (95% CI 0.71-0.99; p=0.04). Heterogeneity was not significant (Cochran's Q 4.47, p=0.1, I2 index 55.3%). Pooled risk ratio...



Extra-abdominal Desmoid Fibromatosis: A review of management, current guidance and unanswered questions

Sat, 20 Feb 2016 00:00:00 +0100

Publication date: Available online 19 February 2016 Source:European Journal of Surgical Oncology (EJSO) Author(s): Nicholas Eastley, Tom McCulloch, Claire Elser, Ivo Hennig, Julia Fairbairn, Alessandro Gronchi, Robert Ashford Extra abdominal desmoid fibromatosis is a complex condition with many recognised treatments including active observation, hormonal therapy, chemotherapy, radiotherapy and surgical resection. There is large variation in the natural history of individual desmoid tumours, with some cases progressing aggressively and others regressing spontaneously when observed alone. This combined with an absence of accurate clinical predictors of a desmoid tumour's behaviour has led to difficulties in identifying which patients would benefit most from aggressive treatment, and...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Association of Active and Sedentary Behaviors with Postmenopausal Estrogen Metabolism

Fri, 19 Feb 2016 18:19:25 +0100

Purpose: Physical activity may reduce endogenous estrogens, but few studies have assessed effects on estrogen metabolism and none have evaluated sedentary behavior in relation to estrogen metabolism. We assessed relationships between accelerometer-measured physical activity and sedentary behavior and 15 urinary estrogens and estrogen metabolites (EM) among postmenopausal controls from a population-based breast cancer case-control study conducted in Poland (2000–2003). Methods: Postmenopausal women (N = 542) were ages 40 to 72 yr and not currently using hormone therapy. Accelerometers, worn for 7 d, were used to derive measures of average activity (counts per day) and sedentary behavior ( (Source: Medicine and Science in Sports and Exercise)



Continuation of Progesterone Implants: Effects of Age, Race, Parity, BMI and the Use of Hormone Therapy for Irregular Bleeding in Adolescent and Adult Populations

Fri, 19 Feb 2016 14:08:31 +0100

1) Analyze the discontinuation rates of progesterone implants (PIs), 2) assess the effect of age, race, parity, and BMI on continuation, and 3) assess the use of hormone therapy for PI-associated irregular bleeding. (Source: Journal of Pediatric and Adolescent Gynecology)



Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)

Fri, 19 Feb 2016 00:00:00 +0100

Conclusions IAD and CAD demonstrated similar efficacy, tolerability, and QoL in men with nonmetastatic PCa. The principal benefit of IAD compared with CAD is a potential cost reduction with comparable OS rates. There are no apparent QoL benefits. Patient summary This randomised trial showed that both intermittent and continuous hormone therapy had similar efficacy, tolerability, and quality-of-life profiles in patients with relapsing M0 or locally advanced prostate cancer. Intermittent therapy may be a valid option for selected patients. Trial registration ClinicalTrials.gov identifier NCT00378690. Intermittent and continuous hormone therapy demonstrated comparable efficacy, tolerability, and quality of life in patients with relapsing M0 or locally advanced prostate cancer. (Source: Euro...



NIH-supported trials test hormonal therapy in older men with low testosterone levels

Thu, 18 Feb 2016 15:46:47 +0100

Testosterone treatment improved sexual function, had smaller effect on walking, vitality. (Source: National Institutes of Health (NIH) News Releases)



Meningiomas in three male‐to‐female transgender subjects using oestrogens/progestogens and review of the literature

Thu, 18 Feb 2016 07:07:23 +0100

Summary Sex hormones have been proposed as a possible risk factor for the development and growth of meningiomas. Hormonal therapy plays a fundamental role in the treatment of male‐to‐female transgenders and needs to be continued after sex reassignment surgery. Usually, this treatment leads to no adverse events; however, its impact on hormone‐related tumours such as meningiomas has not yet been investigated thoroughly. We searched our cohort of 2810 male‐to‐female transgender persons, who have been treated between 1975 and 2010, for patients with meningiomas. Additionally, we conducted a literature search in PubMed and EMBASE. We found three patients who developed a meningioma in male‐to‐female transgenders in addition to five other who have been described in the literature. T...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Work ability in prostate cancer survivors after radical prostatectomy.

Thu, 18 Feb 2016 05:22:02 +0100

CONCLUSION: Increasing age, UL, co-morbidity and time since RP are associated with decreasing post-RP WA. Without specifying the individual therapy, post-RP oncological treatment seems to have an additional negative effect, warranting consideration of patients' work plans when considering post-RP oncological treatment. PMID: 26609896 [PubMed - as supplied by publisher] (Source: Scandinavian Journal of Urology)



Efficacy of extracorporeal ultrasound-guided high intensity focused ultrasound: An evaluation based on controlled trials in China.

Thu, 18 Feb 2016 01:49:02 +0100

CONCLUSIONS: HIFU should be curtailed in resectable cases and be an alternative in inoperable cases; a combination regimen should not be recommended. The Response Evaluation Criteria in Solid Tumors can be applied to HIFU. PMID: 25758333 [PubMed - indexed for MEDLINE] (Source: International Journal of Radiation Biology)



Abstract PL1: Critical Decision Making in Radiation Therapy for Breast Cancer in 2015

Thu, 18 Feb 2016 00:00:00 +0100

In 2005, the EBCTCG meta-analysis demonstrated for the first time that RT after either breast-conserving surgery (BCS) or mastectomy not only reduced local-regional recurrence (LRR), but also improved long-term survival. At the time, they (erroneously) postulated that for every 4 LRR's avoid at 5 years, there was an additional survivor at 15 years. The EBCTCG subsequently adopted 'any first recurrence' as the primary endpoint for the effect of RT based on 1 – RT's established systemic effect in reducing both local and distant recurrence, 2 – that time to LRR is not strictly valid, and 3 – that the ratio between reduction in LRR and improvement in survival no longer held up. The new 'ratio' is that for every 1.5 first recurrences avoided at 10 years, there is an additional survivor at...



Abstract ES3-3: Post-mastectomy breast reconstruction: defining the effects of adjuvant treatment modalities on surgical outcomes

Thu, 18 Feb 2016 00:00:00 +0100

Post-mastectomy breast reconstruction is routinely offered immediately at the time of mastectomy, and can be performed using prosthetic or autologous techniques. Successful surgical outcomes are routine with these procedures, but can be complicated when adjuvant treatment modalities for breast cancer are employed. The most common adjuvant treatments effecting outcomes in post-mastectomy breast reconstruction are radiation, chemotherapy/hormonal therapy, and axillary lymph node dissection.Adjuvant radiation therapy has been shown to increase the complication rate in prosthetic breast reconstruction, specifically with increased rates of implant infection (22%, p=0.0), full-thickness mastectomy skin necrosis (11.5%, p=.001), and expander/implant removal (17.7%, p=0.0). Such complication rates...



Abstract PD1-02: Statin use and breast cancer incidence in the Nurses' health study

Thu, 18 Feb 2016 00:00:00 +0100

ConclusionsOur results indicate that cholesterol-lowering statin therapy neither increases nor decreases breast cancer incidence rate in postmenopausal women. Considering the latest report indicated an increased breast cancer risk among statin users, our neutral findings should reassure physicians that statin therapy for the prevention of cardiovascular disease is safe with respect to breast cancer risk.Citation Format: Ahern TP, Tamimi RM, Chen WY, Garber JE, Eliassen AH, Borgquist S. Statin use and breast cancer incidence in the Nurses' health study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD1-02. (Source: Cancer Research)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04)

Thu, 18 Feb 2016 00:00:00 +0100

Conclusions:The clinical utility of X in the adjuvant setting for breast cancer pts has been proven to improve the prognosis based on the pathological response-guided strategy. Tolerability was consistent with the established safety profile of X in mBC. The benefit to risk balance of the addition of 8 cycles of X to standard adjuvant therapy seems to be satisfied. This evidence might allow the development of personalized individualized treatment based on the response to primary systemic therapy.Citation Format: Toi M, Lee S-J, Lee ES, Ohtani S, Im Y-H, Im S-A, Park B-W, Kim S-B, Yanagita Y, Takao S, Ohno S, Aogi K, Iwata H, Kim A, Sasano H, Yokota I, Ohashi Y, Masuda N. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive dise...



Abstract S3-04: ESR1 coregulator binding inhibitor (ECBI) as a novel therapeutic to target hormone therapy resistant metastatic breast cancer

Thu, 18 Feb 2016 00:00:00 +0100

CONCLUSIONS: The ECBI is a novel agent that targets ESR1 with a unique mechanism of action. ECBI has distinct pharmacologic advantages of oral bioavailability, in vivo stability, and is associated with minimal systemic side effects. Remarkably, ECBI block both native and mutant forms of ESR1 and have activity against therapy resistant breast cancer cell proliferation both in vitro and in vivo and against primary human tumor tissues ex vivo. Thus development of ECBI represents a quantum leap in therapies to target ESR1.Citation Format: Vadlamudi RK, Sareddy GR, Viswanadhapalli S, Lee T-K, Ma S-H, Lee WR, Mann M, Krishnan SR, Gonugunta V, Strand DW, Tekmal RR, Ahn J-M, Raj GV. ESR1 coregulator binding inhibitor (ECBI) as a novel therapeutic to target hormone therapy resistant metastatic brea...



Abstract PD4-04: Psychosocial factors related to interruptions in adjuvant hormonal therapy among women with breast cancer: The breast cancer quality of care study (BQUAL)

Thu, 18 Feb 2016 00:00:00 +0100

Background. Adjuvant hormonal therapy (HT) for hormone-sensitive breast cancer decreases risk of breast cancer recurrence and improves survival. However, some women are non-adherent to this life-saving treatment.Methods. In a cohort of women recruited at diagnosis of breast cancer in an integrated healthcare system, we investigated factors related to HT interruption (≥90 day gap). Serial interviews were conducted at baseline and during treatment to examine psychological factors as well as sociodemographic factors, tumor characteristics, and treatment factors. A series of multivariate models assessed potential predictors of HT interruptions.Results. Of the 569 women in our cohort who initiated HT, 137 (24%) interrupted it, including 18 (3%) who did so prior to the first follow-up intervie...



Abstract P1-01-07: Distribution pattern of Ki67 immunoreactivity in ductal intraepithelial neoplasia (DIN): Correlation with lesion grade and potential utility

Thu, 18 Feb 2016 00:00:00 +0100

In this study, the pattern of distribution of the nuclei immunoreactive with Ki67 was examined in DIN1C (DCIS, grade 1), DIN2 (DCIS, grade2), and DIN3 (DCIS, grade 3) to determine if distinctive patterns could be identified and if these patterns would correlate with lesion grade.METHODS: 47 consecutive DIN cases were retrieved from our departmental files. Of these, 5 qualified as DIN1C, 28 as DIN2 and 14 as DIN3. H 0 indicating absence of necrosis and 2 reflecting comedo type necrosis. Necrosis was more common in the ducts with haphazard Ki67 distribution. The extent of necrosis varied significantly between DIN1c, DIN2 and DIN3 (Chi –square test, P (Source: Cancer Research)